Johnson & Johnson $JNJ Stock Bought by Sanders Morris Harris LLC

Key Points

• Sanders Morris Harris LLC increased its Johnson & Johnson stake by 185.8% in the third quarter, bringing its holdings to 8,197 shares valued at approximately $2.2 million. Institutional investors and hedge funds collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly adjusted EPS of $2.59, beating the $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. The company raised its 2026 guidance to $11.05–$11.15 in adjusted EPS.
• The company declared a quarterly dividend of $1.34 per share, or $5.36 annualized, representing a yield of about 2.1%. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $273.61.

Sanders Morris Harris LLC increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 185.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,197 shares of the company's stock after acquiring an additional 5,329 shares during the period. Sanders Morris Harris LLC's holdings in Johnson & Johnson were worth $2,197,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Auto Owners Insurance Co boosted its position in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Wellington Management Group LLP grew its stake in Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock worth $5,736,851,000 after buying an additional 2,513,321 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock valued at $3,977,506,000 after acquiring an additional 1,225,676 shares during the period. Amundi lifted its position in Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. Finally, Janus Henderson Group PLC grew its position in Johnson & Johnson by 1.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company's stock valued at $1,924,323,000 after buying an additional 148,497 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last three months. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $253.49 on Thursday. The stock's 50 day moving average is $265.80 and its two-hundred day moving average is $249.47. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The company has a market capitalization of $610.89 billion, a PE ratio of 38.41, a P/E/G ratio of 2.54 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The firm's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the business earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts predict that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 62.11%.

Analysts Set New Price Targets

Several research firms have issued reports on JNJ. UBS Group set a $270.00 target price on Johnson & Johnson in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 29th. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Johnson Rice reissued a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $273.61.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ exceeded third-quarter adjusted earnings expectations, reporting EPS of $2.59 versus a $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth engine, with reported 7.9% growth and strong demand for newer products. Johnson & Johnson reports Q3 2026 results and raises 2026 guidance
• Positive Sentiment: The company raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. The improved forecast provides support for the stock despite the quarter’s mixed details. JNJ Q3 earnings call highlights
• Positive Sentiment: JNJ declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and approximately a 2.2% yield, reinforcing its appeal to income-focused investors. Johnson & Johnson announces quarterly dividend

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.